glp-1 obesity drug updates today weight loss drugs leave users low on key nutrients, study finds The FDA approved a new
Description
Researchers determined this using transgenic mice, allowing them to turn off the GLP-1 in the brain to see what happens
doi:10.1210/endo.133.4.8404634
Additionally, if youre living with obesity and struggling to lose weight, GLP-1s effectively support clinically significant weight loss of more than 10% of body weight
On the basis of the differences in the gradients, an average relative biopotency of 14.8% could be inferred for intestinal administration over the full dose range, albeit with this likely to be higher if assessing only lower doses
Meanwhile, another study published in the Journal of the American Medical Association (JAMA) has found that taking tirzepatide drugs like Mounjaro doubles a persons risk of NAION
J., Cao, X
